Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function
- PMID: 25232870
- PMCID: PMC4169480
- DOI: 10.1371/journal.ppat.1004383
Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function
Abstract
Hospitalization of the elderly for invasive pneumococcal disease is frequently accompanied by the occurrence of an adverse cardiac event; these are primarily new or worsened heart failure and cardiac arrhythmia. Herein, we describe previously unrecognized microscopic lesions (microlesions) formed within the myocardium of mice, rhesus macaques, and humans during bacteremic Streptococcus pneumoniae infection. In mice, invasive pneumococcal disease (IPD) severity correlated with levels of serum troponin, a marker for cardiac damage, the development of aberrant cardiac electrophysiology, and the number and size of cardiac microlesions. Microlesions were prominent in the ventricles, vacuolar in appearance with extracellular pneumococci, and remarkable due to the absence of infiltrating immune cells. The pore-forming toxin pneumolysin was required for microlesion formation but Interleukin-1β was not detected at the microlesion site ruling out pneumolysin-mediated pyroptosis as a cause of cell death. Antibiotic treatment resulted in maturing of the lesions over one week with robust immune cell infiltration and collagen deposition suggestive of long-term cardiac scarring. Bacterial translocation into the heart tissue required the pneumococcal adhesin CbpA and the host ligands Laminin receptor (LR) and Platelet-activating factor receptor. Immunization of mice with a fusion construct of CbpA or the LR binding domain of CbpA with the pneumolysin toxoid L460D protected against microlesion formation. We conclude that microlesion formation may contribute to the acute and long-term adverse cardiac events seen in humans with IPD.
Conflict of interest statement
AOB, BM, EIT, and CJO are listed as inventors on patents regarding the use of the synthetic pneumococcal vaccine YLN to prevent invasive pneumococcal disease and cardiac damage. This does not alter our adherence to all PLOS policies on sharing data and materials.
Figures
Similar articles
-
Cell Invasion and Pyruvate Oxidase-Derived H2O2 Are Critical for Streptococcus pneumoniae-Mediated Cardiomyocyte Killing.Infect Immun. 2017 Dec 19;86(1):e00569-17. doi: 10.1128/IAI.00569-17. Print 2018 Jan. Infect Immun. 2017. PMID: 29061707 Free PMC article.
-
Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion.Infect Immun. 2016 Apr 22;84(5):1457-69. doi: 10.1128/IAI.00007-16. Print 2016 May. Infect Immun. 2016. PMID: 26930705 Free PMC article.
-
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling.J Vis Exp. 2015 Apr 7;(98):52590. doi: 10.3791/52590. J Vis Exp. 2015. PMID: 25939051 Free PMC article.
-
Cardiotoxicity during invasive pneumococcal disease.Am J Respir Crit Care Med. 2015 Apr 1;191(7):739-45. doi: 10.1164/rccm.201411-1951PP. Am J Respir Crit Care Med. 2015. PMID: 25629643 Free PMC article. Review.
-
Pathogenesis of pneumococcal inflammation: otitis media.Vaccine. 2000 Dec 8;19 Suppl 1:S38-40. doi: 10.1016/s0264-410x(00)00276-0. Vaccine. 2000. PMID: 11163461 Review.
Cited by
-
Infectious factors in myocarditis: a comprehensive review of common and rare pathogens.Egypt Heart J. 2024 May 24;76(1):64. doi: 10.1186/s43044-024-00493-3. Egypt Heart J. 2024. PMID: 38789885 Free PMC article. Review.
-
The prostaglandin D2 antagonist asapiprant ameliorates clinical severity in young hosts infected with invasive Streptococcus pneumoniae.Infect Immun. 2024 May 7;92(5):e0052223. doi: 10.1128/iai.00522-23. Epub 2024 Apr 17. Infect Immun. 2024. PMID: 38629842
-
The inflammatory spectrum of cardiomyopathies.Front Cardiovasc Med. 2024 Feb 23;11:1251780. doi: 10.3389/fcvm.2024.1251780. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38464847 Free PMC article. Review.
-
Time-resolved RNA-seq analysis to unravel the in vivo competence induction by Streptococcus pneumoniae during pneumonia-derived sepsis.Microbiol Spectr. 2024 Mar 5;12(3):e0305023. doi: 10.1128/spectrum.03050-23. Epub 2024 Feb 2. Microbiol Spectr. 2024. PMID: 38305162 Free PMC article.
-
Pseudomonas aeruginosa pulmonary infection results in S100A8/A9-dependent cardiac dysfunction.PLoS Pathog. 2023 Aug 25;19(8):e1011573. doi: 10.1371/journal.ppat.1011573. eCollection 2023 Aug. PLoS Pathog. 2023. PMID: 37624851 Free PMC article.
References
-
- Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, et al. (2012) Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 125: 773–781. - PubMed
-
- Corrales-Medina VF, Serpa J, Rueda AM, Giordano TP, Bozkurt B, et al. (2009) Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine 88: 154–159. - PubMed
-
- Kaplan V, Clermont G, Griffin MF, Kasal J, Watson RS, et al. (2003) Pneumonia: still the old man's friend? Arch Intern Med 163: 317–323. - PubMed
-
- Kumar S, Wang L, Fan J, Kraft A, Bose ME, et al. (2008) Detection of 11 common viral and bacterial pathogens causing community-acquired pneumonia or sepsis in asymptomatic patients by using a multiplex reverse transcription-PCR assay with manual (enzyme hybridization) or automated (electronic microarray) detection. J Clin Microbiol 46: 3063–3072. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K23 HL096054/HL/NHLBI NIH HHS/United States
- NIH AI27913/AI/NIAID NIH HHS/United States
- P51 RR000164/RR/NCRR NIH HHS/United States
- 5I01BX000505/BX/BLRD VA/United States
- R01 HL075360/HL/NHLBI NIH HHS/United States
- R01 AI027913/AI/NIAID NIH HHS/United States
- R00 AT006704/AT/NCCIH NIH HHS/United States
- UL1 TR001120/TR/NCATS NIH HHS/United States
- NIH AT006704/AT/NCCIH NIH HHS/United States
- K99 AT006704/AT/NCCIH NIH HHS/United States
- I01 BX000505/BX/BLRD VA/United States
- R01 AI078972/AI/NIAID NIH HHS/United States
- N01-HV-00244/HV/NHLBI NIH HHS/United States
- NIH AA009803/AA/NIAAA NIH HHS/United States
- F31 AI104177/AI/NIAID NIH HHS/United States
- KL2 TR001118/TR/NCATS NIH HHS/United States
- HL075360/HL/NHLBI NIH HHS/United States
- HL108054/HL/NHLBI NIH HHS/United States
- R21 HL108054/HL/NHLBI NIH HHS/United States
- NIH HL096054/HL/NHLBI NIH HHS/United States
- RR00164/RR/NCRR NIH HHS/United States
- P50 AA009803/AA/NIAAA NIH HHS/United States
- 268201000036C/PHS HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical